Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Technology cost warning ahead of Spanish cardio programme:

This article was originally published in Clinica

Executive Summary

Spain is preparing to launch a national ischaemic cardiopathy programme by the end of this month. Confirmation of this came with a warning that in order to avoid limiting access to medical technologies in this area, costs must be contained. Alfonso de Castro Beiras, president of the Juan Canalejo cardiology institute, in the northwestern city of A Coruna, was speaking at a meeting held last week in Barcelona by Spanish medical technology industry federation, Fenin. Dr Castro highlighted implantable cardioverter defibrillators (ICDs) as an example of the technologies that are most at risk of being less accessible due to reimbursement policies. The Fenin meeting, held to mark the federation's 25th anniversary, coincided with the Medical Forum Expo 2003 trade fair (For more on both events, see next issue).

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT062707

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel